{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "http://eldaddp.azurewebsites.net/answeredquestions.text?humanIndexable=true&min-date=2018-01-08&AnsweringBody.=Department+of+Health&uin=HL4484", "definition" : "http://eldaddp.azurewebsites.net/meta/answeredquestions.text?humanIndexable=true&min-date=2018-01-08&AnsweringBody.=Department+of+Health&uin=HL4484", "extendedMetadataVersion" : "http://eldaddp.azurewebsites.net/answeredquestions.text?humanIndexable=true&min-date=2018-01-08&AnsweringBody.=Department+of+Health&uin=HL4484&_metadata=all", "first" : "http://eldaddp.azurewebsites.net/answeredquestions.text?_page=0&humanIndexable=true&min-date=2018-01-08&AnsweringBody.=Department+of+Health&uin=HL4484", "hasPart" : "http://eldaddp.azurewebsites.net/answeredquestions.text?humanIndexable=true&min-date=2018-01-08&AnsweringBody.=Department+of+Health&uin=HL4484", "isPartOf" : "http://eldaddp.azurewebsites.net/answeredquestions.text?humanIndexable=true&min-date=2018-01-08&AnsweringBody.=Department+of+Health&uin=HL4484", "items" : [{"_about" : "http://data.parliament.uk/resources/818607", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/818607/answer", "answerText" : {"_value" : "<p>Feeling suicidal, or the risk of suicide, would not be considered to be permanent adverse reactions.<\/p><p>Mefloquine is effective in the prevention and treatment of malaria and is approved by the Medicines and Healthcare products Regulatory Agency (MHRA), which regulates medication in the United Kingdom. As with all medicines, the MHRA keeps the safety of mefloquine under continual review. Mefloquine continues to be recommended as a safe and effective form of malaria prevention by the Advisory Committee on Malaria Prevention, the World Health Organization and other respected organisations who take account of the body of global evidence.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4545", "label" : {"_value" : "Biography information for Lord O'Shaughnessy"}
        }
        , "answeringMemberPrinted" : {"_value" : "Lord O'Shaughnessy"}
        , "dateOfAnswer" : {"_value" : "2018-01-18", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2018-01-18T12:23:37.913Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2018-01-08", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Mefloquine"}
      , "houseId" : {"_value" : "2"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"}
      }
      ], "questionText" : "To ask Her Majesty's Government, further to the Written Answer by Lord O'Shaughnessy on 22 December 2017 (HL4314), whether they consider suicide, as listed in the current mefloquine product information as a psychiatric adverse reaction, to be a permanent adverse reaction.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1861", "label" : {"_value" : "Biography information for The Countess of Mar"}
      }
      , "tablingMemberPrinted" : [{"_value" : "The Countess of Mar"}
      ], "uin" : "HL4484"}
    ], "itemsPerPage" : 10, "page" : 0, "startIndex" : 1, "totalResults" : 1, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]}
}